Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px
Document › Details

PredictImmune Ltd.. (4/2/19). "Press Release: PredictImmune’s First Prognostic Test for IBD PredictSURE IBD, Launches in the UK and Ireland". Cambridge.

Region Region United Kingdom (GB)
Organisations Organisation PredictImmune Ltd.
  Organisation 2 NHS (National Health Service) (GB)
  Group United Kingdom (GB) (govt)
Products Product PredictSURE IBD™ test
  Product 2 blood test
Persons Person Kinnon, Paul (PredictImmune 201807– CEO before ZyGEM + Invitrogen VP + General Manager Applied Markets Business)
  Person 2 Brereton, Sarah (Limewash PR Agency 201908 Director + Founder)
     


The world’s first validated prognostic test for inflammatory bowel disease (IBD) is now available via Cambridge University Hospitals NHS Foundation Trust’s Genomic Laboratory Hub


PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.

Under the agreement, the East Midlands and East of England Genomic Laboratory Hub based at Addenbrooke’s Hospital, will manage and facilitate the fulfilment of orders of PredictSURE IBD™, as well as receive and process all samples.

This agreement gives UK IBD patients access to the world’s first, truly validated and CE-marked prognostic test for guiding treatment options in IBD (Crohn’s disease and ulcerative colitis). It enables both clinicians and patients to understand, at the point of diagnosis, the likely course of disease -differentiating between an aggressive or milder form of the disease - and opens up the possibility of better treatment choices from the outset. With a better understanding of the impact the disease may have, options such as life-style changes to improve the day to day management of the disease can be discussed and implemented much earlier on in the treatment process.

PredictSURE IBD™ is an easy-to-set-up blood-based biomarker test, combined with a sophisticated, proprietary algorithm. The product is based on 10 years of extensive research into gene expression profiling of CD8+ T cells. PredictSURE IBD™ is a major step towards personalised medicine in IBD.

PredictImmune’s CEO, Paul Kinnon commented: “Partnering with Addenbrooke’s to make PredictSURE IBD™ available across the UK and Ireland feels very appropriate, given the long-term nature of our collaboration to date. Working closely with the founding team from the University of Cambridge, and running the PROFILE* study at Addenbrooke’s, has enabled us to forge a strong, trusting relationship over a number of years. I am therefore delighted that we are now in a position to make PredictSURE IBD™ available via the East Midlands and East of England Genomic Laboratory Hub. As a close-knit team, we are excited to see PredictSURE IBD™ become available to UK and Irish patients, particularly because we understand the life-changing benefits that early and accurate prediction of the likely course of their IBD disease can have on their quality of life.”


For more information please visit: www.predictimmune.com


*PredictImmune’s PROFILE study is a randomised, multi-centre, biomarker-stratified open-label trial in patients newly diagnosed with Crohn’s disease. PROFILE aims to demonstrate that a prognostic biomarker can enable delivery of personalised therapy in Crohn’s disease and that it can improve clinical outcomes.


- Ends -


Contacts

Limewash, PR Agency
Sarah Brereton
Director
Tel: +44 (0)1223 813 560

   
Record changed: 2019-08-02

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for PredictImmune Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px




» top